Limits...
Californium versus cobalt brachytherapy combined with external-beam radiotherapy for IIB stage cervical cancer: long-term experience of a single institute.

Janulionis E, Valuckas KP, Liukpetryte S, Samerdokiene V, Atkocius V - J Contemp Brachytherapy (2015)

Bottom Line: The percentage of tumour recurrence was statistically significantly lower in the (252)Cf group with 7.4% versus 17.1% in the (60)Co group (p = 0.02).However, the recurrence of tumour was significantly lower in the (252)Cf group.The incidence of second primary cancers was similar in both groups.

View Article: PubMed Central - PubMed

Affiliation: Radiotherapy and Drug Center.

ABSTRACT

Purpose: The purpose of this paper was to observe and compare long-term curative effects and complications of FIGO stage IIB cervical cancer patients (n = 232) treated with high-dose-rate (HDR) californium ((252)Cf) neutron or cobalt ((60)Co) photon intracavitary brachytherapy (ICBT) combined with external-beam radiotherapy (EBRT).

Material and methods: The EBRT dose to the small pelvis was 50 Gy in both groups. The brachytherapy component of (252)Cf or (60)Co was added in the 3(rd) week of EBRT, 5 fractions were performed once per week resulting in a total ICBT dose of 40 Gy/Gyeq (point A).

Results: Overall survival (OS) at 5, 10 and 15 years was 63.6%, 50.4% and 38.8% in the (252)Cf group and 62.2%, 50.5%, 39.9%, in the (60)Co group, respectively (p = 0.74). The percentage of tumour recurrence was statistically significantly lower in the (252)Cf group with 7.4% versus 17.1% in the (60)Co group (p = 0.02). Second primary cancers have developed similarly 9.1% and 8.1% cases for (252)Cf and (60)Co groups, respectively.

Conclusions: Our long-term retrospective study comparing (252)Cf and (60)Co isotopes with brachytherapy in combined treatment of FIGO IIB stage cervix carcinoma patients shows, that overall survival in the both groups are similar. However, the recurrence of tumour was significantly lower in the (252)Cf group. The incidence of second primary cancers was similar in both groups.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier disease-free and overall survival curves of IIB FIGO stage cervical cancer patients treated with EBRT and 60Co-ICBT
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4663213&req=5

Figure 0002: Kaplan-Meier disease-free and overall survival curves of IIB FIGO stage cervical cancer patients treated with EBRT and 60Co-ICBT

Mentions: The survival rates were calculated from the first treatment date to the last follow-up examination. The survival rates are shown in Figures 1 and 2. Overall survival at 5, 10, and 15 years was 63.6%, 50.4% and 38.8% in the 252Cf group, and 62.2%, 50.5%, 39.9% in the 60Co group, respectively (p = 0.74).


Californium versus cobalt brachytherapy combined with external-beam radiotherapy for IIB stage cervical cancer: long-term experience of a single institute.

Janulionis E, Valuckas KP, Liukpetryte S, Samerdokiene V, Atkocius V - J Contemp Brachytherapy (2015)

Kaplan-Meier disease-free and overall survival curves of IIB FIGO stage cervical cancer patients treated with EBRT and 60Co-ICBT
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4663213&req=5

Figure 0002: Kaplan-Meier disease-free and overall survival curves of IIB FIGO stage cervical cancer patients treated with EBRT and 60Co-ICBT
Mentions: The survival rates were calculated from the first treatment date to the last follow-up examination. The survival rates are shown in Figures 1 and 2. Overall survival at 5, 10, and 15 years was 63.6%, 50.4% and 38.8% in the 252Cf group, and 62.2%, 50.5%, 39.9% in the 60Co group, respectively (p = 0.74).

Bottom Line: The percentage of tumour recurrence was statistically significantly lower in the (252)Cf group with 7.4% versus 17.1% in the (60)Co group (p = 0.02).However, the recurrence of tumour was significantly lower in the (252)Cf group.The incidence of second primary cancers was similar in both groups.

View Article: PubMed Central - PubMed

Affiliation: Radiotherapy and Drug Center.

ABSTRACT

Purpose: The purpose of this paper was to observe and compare long-term curative effects and complications of FIGO stage IIB cervical cancer patients (n = 232) treated with high-dose-rate (HDR) californium ((252)Cf) neutron or cobalt ((60)Co) photon intracavitary brachytherapy (ICBT) combined with external-beam radiotherapy (EBRT).

Material and methods: The EBRT dose to the small pelvis was 50 Gy in both groups. The brachytherapy component of (252)Cf or (60)Co was added in the 3(rd) week of EBRT, 5 fractions were performed once per week resulting in a total ICBT dose of 40 Gy/Gyeq (point A).

Results: Overall survival (OS) at 5, 10 and 15 years was 63.6%, 50.4% and 38.8% in the (252)Cf group and 62.2%, 50.5%, 39.9%, in the (60)Co group, respectively (p = 0.74). The percentage of tumour recurrence was statistically significantly lower in the (252)Cf group with 7.4% versus 17.1% in the (60)Co group (p = 0.02). Second primary cancers have developed similarly 9.1% and 8.1% cases for (252)Cf and (60)Co groups, respectively.

Conclusions: Our long-term retrospective study comparing (252)Cf and (60)Co isotopes with brachytherapy in combined treatment of FIGO IIB stage cervix carcinoma patients shows, that overall survival in the both groups are similar. However, the recurrence of tumour was significantly lower in the (252)Cf group. The incidence of second primary cancers was similar in both groups.

No MeSH data available.


Related in: MedlinePlus